Shaleen R Vasavada1, Ryan W Dobbs1, André A Kajdacsy-Balla1, Michael R Abern1, Daniel M Moreira2. 1. Departments of Urology and Pathology (AAK-B), University of Illinois at Chicago, Chicago, Illinois. 2. Departments of Urology and Pathology (AAK-B), University of Illinois at Chicago, Chicago, Illinois. Electronic address: moreira@uic.edu.
Abstract
PURPOSE: We performed a comprehensive literature review and meta-analysis to evaluate the association of inflammation on prostate needle biopsies and prostate cancer risk. MATERIALS AND METHODS: We searched Embase®, PubMed® and Web of Science™ from January 1, 1990 to October 1, 2016 for abstracts containing the key words prostate cancer, inflammation and biopsy. Study inclusion criteria were original research, adult human subjects, cohort or case-control study design, histological inflammation on prostate needle biopsy and prostate cancer on histology. Two independent teams reviewed abstracts and extracted data from the selected manuscripts. Combined ORs and 95% CIs of any, acute and chronic inflammation were calculated using the random effects method. RESULTS: Of the 1,030 retrieved abstracts 46 underwent full text review and 25 were included in the final analysis, comprising a total of 20,585 subjects and 6,641 patients with prostate cancer. There was significant heterogeneity among studies (I2 = 84.4%, p <0.001). The presence of any inflammation was significantly associated with a lower prostate cancer risk in 25 studies (OR 0.455, 95% CI 0.337-0.573). There was no evidence of publication bias (p >0.05). When subanalyzed by inflammation type, acute inflammation in 4 studies and chronic inflammation in 15 were each associated with a lower prostate cancer risk (OR 0.681, 95% CI 0.450-0.913 and OR 0.499, 95% CI 0.334-0.665, respectively). CONCLUSIONS: In a meta-analysis of 25 studies inflammation on prostate needle biopsy was associated with a lower prostate cancer risk. Clinically the presence of inflammation on prostate needle biopsy may lower the risk of a subsequent prostate cancer diagnosis.
PURPOSE: We performed a comprehensive literature review and meta-analysis to evaluate the association of inflammation on prostate needle biopsies and prostate cancer risk. MATERIALS AND METHODS: We searched Embase®, PubMed® and Web of Science™ from January 1, 1990 to October 1, 2016 for abstracts containing the key words prostate cancer, inflammation and biopsy. Study inclusion criteria were original research, adult human subjects, cohort or case-control study design, histological inflammation on prostate needle biopsy and prostate cancer on histology. Two independent teams reviewed abstracts and extracted data from the selected manuscripts. Combined ORs and 95% CIs of any, acute and chronic inflammation were calculated using the random effects method. RESULTS: Of the 1,030 retrieved abstracts 46 underwent full text review and 25 were included in the final analysis, comprising a total of 20,585 subjects and 6,641 patients with prostate cancer. There was significant heterogeneity among studies (I2 = 84.4%, p <0.001). The presence of any inflammation was significantly associated with a lower prostate cancer risk in 25 studies (OR 0.455, 95% CI 0.337-0.573). There was no evidence of publication bias (p >0.05). When subanalyzed by inflammation type, acute inflammation in 4 studies and chronic inflammation in 15 were each associated with a lower prostate cancer risk (OR 0.681, 95% CI 0.450-0.913 and OR 0.499, 95% CI 0.334-0.665, respectively). CONCLUSIONS: In a meta-analysis of 25 studies inflammation on prostate needle biopsy was associated with a lower prostate cancer risk. Clinically the presence of inflammation on prostate needle biopsy may lower the risk of a subsequent prostate cancer diagnosis.
Authors: Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Giovanni Novella; Tania Processali; Marco Pirozzi; Nelia Amigoni; Riccardo Rizzetto; Aliasger Shakir; Arianna Mariotto; Matteo Brunelli; Maria Angela Cerruto; Giovanni Enrico Cacciamani; Filippo Migliorini; Salvatore Siracusano; Walter Artibani Journal: World J Urol Date: 2019-06-01 Impact factor: 4.226
Authors: Alessandro Tafuri; Marco Sebben; Giovanni Novella; Marco Pirozzi; Tania Processali; Aliasger Shakir; Riccardo Rizzetto; Nelia Amigoni; Riccardo Bernasconi; Matteo Brunelli; Maria A Cerruto; Salvatore Siracusano; Alessandro Antonelli; Walter Artibani; Antonio B Porcaro Journal: Arab J Urol Date: 2020-05-13
Authors: Marvin E Langston; Karen S Sfanos; Saira Khan; Trang Q Nguyen; Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-02 Impact factor: 4.090
Authors: Salvatore M Bruno; Ugo G Falagario; Nicola d'Altilia; Marco Recchia; Vito Mancini; Oscar Selvaggio; Francesca Sanguedolce; Francesco Del Giudice; Martina Maggi; Matteo Ferro; Angelo Porreca; Alessandro Sciarra; Ettore De Berardinis; Carlo Bettocchi; Gian Maria Busetto; Luigi Cormio; Giuseppe Carrieri Journal: Front Oncol Date: 2021-05-20 Impact factor: 6.244